<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Because ACE insertion/deletion (I/D) polymorphism has been shown to be associated with <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:hpo ids='HP_0001677'>coronary artery diseases</z:hpo>, and diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, and because plasma ACE concentration has been found to be associated with plasma <z:chebi fb="0" ids="17855">triglyceride</z:chebi> and total cholesterol levels in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, the goal of this study was to investigate whether ACE gene I/D polymorphism is associated with <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> in Chinese subjects with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: A total of 711 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and 750 control subjects were studied </plain></SENT>
<SENT sid="2" pm="."><plain>The ACE I/D polymorphism was determined by PCR </plain></SENT>
<SENT sid="3" pm="."><plain>The definition and criteria of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> used in this study matched those proposed in the 1998 World Health Organization classification </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Of 711 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, 534 (75.1%) fulfilled the criteria for <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The prevalence of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> in control subjects with II, ID, and DD genotype was 9.4, 11.5, and 15.4%, respectively, and in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, it was 68.6, 79.2, and 86.1%, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>The ACE I/D polymorphism was significantly associated with the syndrome in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (P = 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>When pooling the control subjects with diabetic patients, the prevalence of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> in the whole study group with II, ID, and DD genotype was 37.9, 44.5, and 51.0%, respectively, and ACE I/D polymorphism was still significantly associated with <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> (P = 0.003) </plain></SENT>
<SENT sid="8" pm="."><plain>Diabetic patients with DD genotype were also found to have a higher prevalence of <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> (II/ID/DD = 43.1/53.1/65.8%, P &lt; 0.001) and <z:mp ids='MP_0002871'>albuminuria</z:mp> (36.0/44.6/50.6%, P = 0.018) and to have higher serum <z:chebi fb="0" ids="17855">triglyceride</z:chebi> levels (II, ID, and DD = 155 +/- 114, 170 +/- 140, and 199 +/- 132 mg/dl, respectively, P &lt; 0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>Control subjects with DD genotype were also found to have a higher prevalence of <z:mp ids='MP_0002871'>albuminuria</z:mp> or more advanced <z:hpo ids='HP_0000112'>nephropathy</z:hpo> (II/ID/DD = 5.7/14.0/15.4%, P = 0.001), whereas the prevalence of <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> was not found to be statistically different in the control group </plain></SENT>
<SENT sid="10" pm="."><plain>When pooling control with diabetic subjects, ACE genotype could still be significantly associated with <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> (II/ID/DD = 34.7/41.3/52.2%, P &lt; 0.001) and <z:mp ids='MP_0002871'>albuminuria</z:mp> or more advanced <z:hpo ids='HP_0000112'>nephropathy</z:hpo> (20.3/28.9/33.1%, P &lt; 0.001) </plain></SENT>
<SENT sid="11" pm="."><plain>Diabetic patients with <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> were found to have higher serum <z:chebi fb="3" ids="27226">uric acid</z:chebi> levels than those without <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> (6.4 +/- 1.8 vs. 5.3 +/- 1.4 mg/dl, P &lt; 0.01) </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: The ACE I/D polymorphism was found to be associated with <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> in Chinese patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="13" pm="."><plain>This finding may provide genetic evidence to explain the clustering of <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> and suggests that the renin-angiotensin system is involved in the pathophysiology of metabolic derangement in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>